KZIA (Kazia Therapeutics) Net earnings per share growth this year

KZIA (Kazia Therapeutics) - company brandmark

Current annual EPS growth reflects the dynamics of Kazia Therapeutics (KZIA), the developer of paxalisib, which is capable of crossing the blood-brain barrier for glioblastoma therapy, with the indicator recorded at 22.90. Business prospects rely on clinical test results and funding, while the stability of the R&D team is ensured by the recruitment of specialized experts and trial managers.

Earnings per share growth in current year: Kazia Therapeutics Ltd (KZIA) for 07/04/2022 - 11/18/2026

Financial and market metric breakdowns for Kazia Therapeutics Ltd (KZIA)

Summary company analysis:KZIA Kazia Therapeutics Limited
Signature product of Kazia Therapeutics Limited

This metric is calculated as the year-over-year percentage change in net earnings per share, reflecting the business scaling rate. An increase in this value signals accelerating profitability, while a decrease indicates stagnation or losses. For Kazia Therapeutics (KZIA), the annual EPS trend depends directly on the clinical success of paxalisib in treating brain tumors and its ability to cross the blood-brain barrier.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences Inc INBX|I-Mab - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year herontx.com|NVCT: Earnings growth in current year|Net earnings per share change in current year Coherus CHRS|Net earnings per share growth this year CRBP|Earnings per share growth rate in current year Cardiff Oncology CRDF|Net earnings per share growth this year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Earnings per share increase in current year|Lixte Biotechnology - Net earnings per share growth this year|Net earnings per one share growth for the current year CTXR (Citius Pharma)|Cellectar - Earnings growth in current year|Earnings per share increase in current year BLRX (BioLineRx Corp)|CANF: Earnings growth in current year|Earnings per share growth rate in current year Aprea (APRE)|Earnings per share growth in current year silexion.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year